8th Jan 2016 08:35
(ShareCast News) - Tiziana Life Sciences revealed the great strides it had made in the quest for cancer-fighting drugs this week, as part of its research partnership with the Cardiff University / Prifysgol Caerdydd. The AIM-listed biotechnology company, which focuses on targeted drugs to treat disea
Read more22nd Dec 2014 11:46
Tiziana Life Sciences has been granted an exclusive license to develop and commercialise Novimmune SA's CD3 receptor monoclonal antibody foralumab. Foralumab can be utilised for a range of autoimmune and inflammatory diseases, such multiple sclerosis, type-1 diabetes, inflammatory bowel disease, pso
Read more